Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality.
about
Tiotropium HandiHaler in the treatment of COPD: a safety reviewRebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? Yes.Réfutation: Faut-il éviter les β-agonistes dans les cas de bronchopneumopathies chroniques obstructives modérées et graves?: OUI.Protective effects of tiotropium alone or combined with budesonide against cadmium inhalation induced acute neutrophilic pulmonary inflammation in rats.
P2860
Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bronchodilators in COPD: impac ...... e exacerbations and mortality.
@en
Bronchodilators in COPD: impac ...... e exacerbations and mortality.
@nl
type
label
Bronchodilators in COPD: impac ...... e exacerbations and mortality.
@en
Bronchodilators in COPD: impac ...... e exacerbations and mortality.
@nl
prefLabel
Bronchodilators in COPD: impac ...... e exacerbations and mortality.
@en
Bronchodilators in COPD: impac ...... e exacerbations and mortality.
@nl
P2860
P356
P1476
Bronchodilators in COPD: impac ...... e exacerbations and mortality.
@en
P2093
Shelley R Salpeter
P2860
P356
10.2147/COPD.2007.2.1.11
P407
P577
2007-01-01T00:00:00Z